Insights into apoptosis mechanisms induced by DNA-damaging agents in Burkitt's lymphoma cells

Cancer Investigation

Volumn 27, Issue 8, 2009, Pages 830-835

  Simões Magluta, Eliane Pereira ^a   Da Cunha Vasconcelos, Flavia ^a   Maia, Raquel Ciuvalschi ^a   Klumb, Claudete Esteves ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Apoptosis; Burkitt's lymphoma; DNA damage; P53

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; LIPOCORTIN 5; PROTEIN P21; PROTEIN P53; SURVIVIN;

APOPTOSIS; ARTICLE; BURKITT LYMPHOMA; CELL CYCLE ARREST; CONTROLLED STUDY; GAMMA IRRADIATION; GENE MUTATION; HUMAN; HUMAN CELL; LYMPHOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSACTIVATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BURKITT LYMPHOMA; CELL CYCLE; CELL LINE, TUMOR; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA DAMAGE; DOXORUBICIN; ETOPOSIDE; GAMMA RAYS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; MUTATION; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 70249090726     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900902849624     Document Type: Article

References (34)

1. Lane, D.P. Cancer. p53, guardian of the genome. Nature 1992, 358(6381), 15-16.
2. Vogelstein, B.; Kinzler, K.W. p53 function and dysfunction. Cell 1992, 70(4), 523-526.
3. Chipuk, J.E.; Maurer, U.; Green, D.R.; Schuler, M. Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell 2003, 4(5), 371-381
4. Chipuk, J.E.; Green, D.R. Cytoplasmic p53: bax and forward. Cell Cycle 2004, 3(4), 429-431.
5. Thompson, C.B. Apoptosis in the pathogenesis and treatment of disease. Science 1995, 267(5293), 1456-1462.
6. Duckett, C.S.; Nava, V.E.; Gedrich, R.W.; Clem, R.J.; Van Dongen, J.L.; Gilfillan, M.C.; Shiels, H.; Hardwick, J.M.; Thompson, C.B. A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors. EMBO J 1996, 15(11), 2685-2694.
7. Ambrosini, G.; Adida, C.; Altieri, D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997, 3(8), 917-921.
8. Altieri, D.C. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 2001 7(12), 542-547.
9. Stauber, R.H.; Mann, W.; Knauer, S.K. Nuclear and cytoplasmic survivin: molecular mechanism, prognostic and therapeutic potential. Cancer Res 2007, 67(13), 5999-6002. (Pubitemid 47037475)
10. Li, F.; Ambrosini, G.; Chu, E.Y.; Plescia, J.; Tognin, S.; Marchisio, P.C.; Altieri, D.C. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998, 396(6711), 580-584.
11. Hoffman, W.H.; Biade, S.; Zilfou, J.T.; Chen, J.; Murphy, M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002, 277(5), 3247-3257.
12. Zhou, M.; Gu, L.; Li, F.; Zhu, Y.; Woods, W.G.; Findley, H.W. DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J Pharmacol Exp Ther 2002, 303(1), 124-131.
13. Farrell, P.J.; Allan, G.J.; Shanahan, F.; Vousden, K.H.; Crook, T. p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J 1991, 10(10), 2879-2887.
14. Debuire, B.; Romano, J.; Ehrhart, J.C.; Fiscella, M.; May, E.; Appella, E.; May, P. p53 mutations in Raji cells: characterization and localization relative to other Burkitt's lymphomas. Oncogene 1992, 7 (11), 2161-2167.
15. Gaidano, G.; Ballerini, P.; Gong, J.Z.; Inghirami, G.; Neri, A.; Newcomb, E.W.; Magrath, I.T.; Knowles, D.M.; Dalla-Favera, R. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci U.S.A. 1991, 88(12), 5413-5417.
16. Seabright, M.A. A rapid banding technique for human chromosomes. Lancet 1971, 2(7731), 971-972.
17. Drexler, H.G.; Dirks, W.G.; Matsuo, Y.; MacLeod, R.A. False leukemia-lymphoma cell lines: an update on over 500 cell lines. Leukemia 2003, 17(2), 416-426.
18. Karpova, M.B.; Schoumans, J.; Ernberg, I.; Henter, J.I.; Norden-skjöld, M.; Fadeel, B. Raji revisited: cytogenetics of the original Burkitt's lymphoma cell line. Leukemia 2005, 19(1), 159-161.
19. Karpova, M.B.; Schoumans, J.; Blennow.; E.; Ernberg, I.; Hen-ter, J.I.; Smirnov, A.F.; Nordenskjöld, M.; Fadeel, B. Combined spectral karyotyping, comparative genomic hybridization, and in vitro apoptyping of a panel of Burkitt's lymphoma-derived B cell lines reveals an unexpected complexity of chromosomal aberrations and a recurrence of specific abnormalities in chemoresistant cell lines. Int J Oncol 2006, 28(3), 605-617.
20. Benchimol, S. p53-dependent pathways of apoptosis. Cell Death Differ 2001, 8(11), 1049-1051.
21. Klumb, C.E.; Furtado, D.R.; de Resende, L.M.; Carriço M.K.; Coelho, A.M.; de Meis, E.; Maia, R.C.; Rumjanek, F.D. DNA sequence profile of TP53 gene mutations in childhood B-cell non-Hodgkin's lymphomas: prognostic implications. Eur J Haematol 2003, 71(2), 81-90.
22. Brown, J.M.; Wouters, B.G. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1999, 59(7), 1391-1399.
23. Soussi, T.; Béroud, C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001, 1(3), 233-240.
24. O'Connor, P.M.; Jackman, J.; Jondle, D.; Bhatia, K.; Magrath, I.; Kohn, K.W. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res 1993, 53(20), 4776-4780.
25. Fan, S.; el-Deiry, W.S.; Bae, I.; Freeman, J.; Jondle, D.; Bhatia, K.; Fornace, A.J., Jr.; Magrath, I.; Kohn, K.W.; O'Connor, P.M. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 1994, 54(22), 5824-5830.
26. Allday, M.J.; Inman, G.J.; Crawford, D.H.; Farrell, P.J. DNA damage in human B cells can induce apoptosis, proceeding from G1/S when p53 is transactivation competent and G2/M when it is transactivation defective. EMBO J 1995, 14(20) 4994-5005.
27. Ryan, K.M.; Vousden, K.H. Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. Mol Cell Biol 1998, 18(7), 3692-3698.
28. Rowan, S.; Ludwig, R.L.; Haupt, Y.; Bates, S.; Lu, X.; Oren, M.; Vousden, K.H. Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J 1996, 15(4), 827-838.
29. Kakudo, Y.; Shibata, H.; Otsuka, K.; Kato, S.; Ishioka, C. Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s. Cancer Res 2005, 65(6), 2108-2114.
30. Doucet, J.P.; Hussain, A.; Al-Rasheed, M.; Gaidano, G.; Gutiérrez, M.I.; Magrath, I.; Bhatia, K. Differences in the expression of apop-totic proteins in Burkitt's lymphoma cell lines: potential models for screening apoptosis-inducing agents. Leuk Lymphoma 2004, 4 5(2), 357-362.
31. Wade, M.; Allday, M.J. Epstein-Barr virus suppresses a G(2)/M checkpoint activated by genotoxins. Mol Cell Biol 2000, 20(4), 1344-1360.
32. Kelly, G.L.; Milner, A.E.; Tierney, R.J.; Croom-Carter, D.S.; Alt-mann, M.; Hammerschmidt, W.; Bell, A.I.; Rickinson, A.B. Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A, -3B, and -3C expression in Burkitt's lym-phoma cells and with increased resistance to apoptosis. J Virol 2005, 79(16), 10709-10717.
33. Leao, M.; Anderton, E.; Wade, M.; Meekings, K.; Allday, M.J. Epstein-Barr virus-induced resistance to drugs that activate the mitotic spindle assembly checkpoint in Burkitt's lymphoma cells. J Virol 2007, 81(1), 248-260.
34. Lindström, M.S.; Klangby, U.; Wiman, K.G. p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53. Oncogene 2001, 20, 2171-2177.